This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
March 10, 2014 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (the "Company") (NASDAQ: ANIP), today announced the closing of its previously announced underwritten public offering of 1,612,903 shares of common stock, at a price to the public of
$31.00 per share and for gross proceeds of
$50.0 million. The shares include 210,378 shares of common stock sold pursuant to the over-allotment option granted by ANI to the underwriters, which option was exercised in full. ANI expects net proceeds of the offering will be approximately
$46.8 million, after deducting underwriting commissions and other offering expenses. Oppenheimer & Co. Inc. and Roth Capital Partners acted as joint book-running managers for the offering.
Arthur S. Przybyl, President and CEO, stated, "We are thrilled with the response we received from interested investors in this offering. The proceeds from this offering are intended to enable ANI's growth through acquisitions and to further our product pipeline. ANI currently has 44 products under various stages of development, with a combined market of over
$1.7 billion, per IMS Health."
The securities described above were issued by ANI pursuant to its existing shelf registration statement under the Securities Act of 1933, as amended. A prospectus supplement and accompanying prospectus related to the offering was filed with the SEC on
March 5, 2014. Copies of the prospectus supplement and the accompanying prospectus relating to this offering may be obtained by contacting Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor,
New York, NY 10004, or by telephone at (212) 667-8563, or by email at
EquityProspectus@opco.com, or from Roth Capital Partners, LLC, Attention: Equity Capital Markets, 888 San Clemente Drive,
Newport Beach, CA 92660, (800) 678-9147,
About ANI Pharmaceuticals
The Company is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company's targeted areas of product development currently include narcotics, oncolytics (anti-cancers), hormones and steroids, and complex formulations involving extended release and combination products. For more information, please visit ANI's website,
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the potential benefits of the recent Merger, the Company's plans, objectives, expectations and intentions with respect to future operations and products, the anticipated financial position, operating results and growth prospects of the Company and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "plans," "potential," "future," "believes," "intends," "continue," other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, subject to change. You should not place undue reliance on those statements because they are subject to numerous uncertainties, risks and other factors relating to the Company's operations and business environment and other factors, all of which are difficult to predict and many of which are beyond the Company's control.